Cyclin-Dependent Kinase 7 (39 kDa Protein Kinase or CDK-Activating Kinase 1 or TFIIH Basal Transcription Factor Complex Kinase Subunit or EC 2.7.11.22) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Cyclin-Dependent Kinase 7 (39 kDa Protein Kinase or CDK-Activating Kinase 1 or TFIIH Basal Transcription Factor Complex Kinase Subunit or EC 2.7.11.22) - Pipeline Review, H1 2016

Cyclin-Dependent Kinase 7 (39 kDa Protein Kinase or CDK-Activating Kinase 1 or TFIIH Basal Transcription Factor Complex Kinase Subunit or EC 2.7.11.22) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Cyclin-Dependent Kinase 7 (39 kDa Protein Kinase or CDK-Activating Kinase 1 or TFIIH Basal Transcription Factor Complex Kinase Subunit or EC 2.7.11.22) - Pipeline Review, H1 2016
Published Jun 30, 2016
63 pages — Published Jun 30, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Cyclin-Dependent Kinase 7 (39 kDa Protein Kinase or CDK-Activating Kinase 1 or TFIIH Basal Transcription Factor Complex Kinase Subunit or EC 2.7.11.22) - Pipeline Review, H1 2016, provides in depth analysis on Cyclin-Dependent Kinase 7 (39 kDa Protein Kinase or CDK-Activating Kinase 1 or TFIIH Basal Transcription Factor Complex Kinase Subunit or EC 2.7.11.22) targeted pipeline therapeutics.

The report provides comprehensive information on the Cyclin-Dependent Kinase 7 (39 kDa Protein Kinase or CDK-Activating Kinase 1 or TFIIH Basal Transcription Factor Complex Kinase Subunit or EC 2.7.11.22), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Cyclin-Dependent Kinase 7 (39 kDa Protein Kinase or CDK-Activating Kinase 1 or TFIIH Basal Transcription Factor Complex Kinase Subunit or EC 2.7.11.22) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Cyclin-Dependent Kinase 7 (39 kDa Protein Kinase or CDK-Activating Kinase 1 or TFIIH Basal Transcription Factor Complex Kinase Subunit or EC 2.7.11.22)
- The report reviews Cyclin-Dependent Kinase 7 (39 kDa Protein Kinase or CDK-Activating Kinase 1 or TFIIH Basal Transcription Factor Complex Kinase Subunit or EC 2.7.11.22) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Cyclin-Dependent Kinase 7 (39 kDa Protein Kinase or CDK-Activating Kinase 1 or TFIIH Basal Transcription Factor Complex Kinase Subunit or EC 2.7.11.22) targeted therapeutics and enlists all their major and minor projects
- The report assesses Cyclin-Dependent Kinase 7 (39 kDa Protein Kinase or CDK-Activating Kinase 1 or TFIIH Basal Transcription Factor Complex Kinase Subunit or EC 2.7.11.22) targeted therapeutics based on mechanism of action (MoA), route of administrati

  
Source:
Document ID
GMDHC0315TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents24
  List of Tables51
  List of Figures51
Introduction61
  Global Markets Direct Report Coverage61
Cyclin-Dependent Kinase 7 (39 kDa Protein Kinase or CDK-Activating Kinase 1 or TFIIH Basal Transcription Factor Complex Kinase Subunit or EC 2.7.11.22) Overview71
Therapeutics Development84
  Cyclin-Dependent Kinase 7 (39 kDa Protein Kinase or CDK-Activating Kinase 1 or TFIIH Basal Transcription Factor Complex Kinase Subunit or EC 2.7.11.22) Products under Development by Stage of Development81
  Cyclin-Dependent Kinase 7 (39 kDa Protein Kinase or CDK-Activating Kinase 1 or TFIIH Basal Transcription Factor Complex Kinase Subunit or EC 2.7.11.22) Products under Development by Therapy Area91
  Cyclin-Dependent Kinase 7 (39 kDa Protein Kinase or CDK-Activating Kinase 1 or TFIIH Basal Transcription Factor Complex Kinase Subunit or EC 2.7.11.22) Products under Development by Indication102
Cyclin-Dependent Kinase 7 (39 kDa Protein Kinase or CDK-Activating Kinase 1 or TFIIH Basal Transcription Factor Complex Kinase Subunit or EC 2.7.11.22) Pipeline Products Glance122
  Late Stage Products121
  Early Stage Products131
Cyclin-Dependent Kinase 7 (39 kDa Protein Kinase or CDK-Activating Kinase 1 or TFIIH Basal Transcription Factor Complex Kinase Subunit or EC 2.7.11.22) Products under Development by Companies143
Cyclin-Dependent Kinase 7 (39 kDa Protein Kinase or CDK-Activating Kinase 1 or TFIIH Basal Transcription Factor Complex Kinase Subunit or EC 2.7.11.22) Products under Development by Universities/Institutes172
Cyclin-Dependent Kinase 7 (39 kDa Protein Kinase or CDK-Activating Kinase 1 or TFIIH Basal Transcription Factor Complex Kinase Subunit or EC 2.7.11.22) Therapeutics Assessment195
  Assessment by Monotherapy/Combination Products191
  Assessment by Mechanism of Action201
  Assessment by Route of Administration212
  Assessment by Molecule Type231
Cyclin-Dependent Kinase 7 (39 kDa Protein Kinase or CDK-Activating Kinase 1 or TFIIH Basal Transcription Factor Complex Kinase Subunit or EC 2.7.11.22) Companies Involved in Therapeutics Development245
  Aurigene Discovery Technologies Limited241
  Beta Pharma, Inc.251
  Cyclacel Pharmaceuticals, Inc.261
  Syros Pharmaceuticals, Inc.271
  Tragara Pharmaceuticals, Inc.281
Cyclin-Dependent Kinase 7 (39 kDa Protein Kinase or CDK-Activating Kinase 1 or TFIIH Basal Transcription Factor Complex Kinase Subunit or EC 2.7.11.22) Drug Profiles2919
  BS-181L Drug Profile291
  CYC-065 Drug Profile303
  sapacitabine + seliciclib Drug Profile333
  seliciclib Drug Profile362
  Small Molecule to Inhibit CDK7 for Oncology Drug Profile381
  Small Molecule to Inhibit CDK7 for Small Cell Lung Cancer Drug Profile391
  Small Molecules to Inhibit Cyclin-Dependent Kinase 7 for Oncology, Inflammation and Infectious Diseases Drug Profile401
  SY-1365 Drug Profile412
  SY-351 Drug Profile432
  TG-02 Drug Profile453
Cyclin-Dependent Kinase 7 (39 kDa Protein Kinase or CDK-Activating Kinase 1 or TFIIH Basal Transcription Factor Complex Kinase Subunit or EC 2.7.11.22) Dormant Projects481
Cyclin-Dependent Kinase 7 (39 kDa Protein Kinase or CDK-Activating Kinase 1 or TFIIH Basal Transcription Factor Complex Kinase Subunit or EC 2.7.11.22) Discontinued Products491
Cyclin-Dependent Kinase 7 (39 kDa Protein Kinase or CDK-Activating Kinase 1 or TFIIH Basal Transcription Factor Complex Kinase Subunit or EC 2.7.11.22) Featured News &Press Releases5012
  Jun 10, 2016: Syros Pharmaceuticals Presents Data Demonstrating Significant Anti-Tumor Activity of its Lead Drug Candidate SY-1365 at 21st Congress of the European Hematology Association501
  Jun 06, 2016: Cyclacel Reports Updated Data From Its DNA Damage Response Program on Seliciclib and Sapacitabine Combination in Patients With Solid Tumors at ASCO511
  May 19, 2016: Cyclacel s Seliciclib-Sapacitabine Abstract Selected for Oral Presentation at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting521
  May 19, 2016: Syros Pharmaceuticals to Present on SY-1365 at 21st Congress of the European Hematology Association531
  Apr 20, 2016: Syros Pharmaceuticals Presents New Data Demonstrating Significant Anti-Tumor Activity of its Selective CDK7 Inhibitor in Preclinical Models of Acute Myeloid Leukemia531
  Apr 18, 2016: Cyclacel s Second-Generation CDK2/9 Inhibitor, CYC065, is an Effective Inducer of Cell Death in B-cell Lymphoma and Synergizes With Bcl-2 or BET Inhibitors541
  Apr 15, 2016: Aurigene to Present its CDK7 Covalent Inhibitor Program at AACR Annual Conference551
  Mar 16, 2016: Syros Pharmaceuticals to Present Preclinical Data on CDK7 Inhibitor Program in Blood Cancers at Upcoming AACR Annual Meeting561
  Dec 14, 2015: Molecular Basis for Development of Cyclacel s CYC065 CDK2/9 Inhibitor in Triple-Negative Breast Cancer Presented at San Antonio Breast Cancer Symposium571
  Dec 05, 2015: Syros Pharmaceuticals Presents New Preclinical Data Demonstrating Significant Anti-Tumor Activity of First-in-Class Selective CDK7 Inhibitor in Models of Acute Leukemias571
  Nov 23, 2015: CYC065, Cyclacel's Novel CDK2/9 Inhibitor, Prolongs Survival in MYCN-Addicted Neuroblastoma Models581
  Nov 09, 2015: Mechanistic Rationale for CYC065, Cyclacel's CDK2/9 Inhibitor, in Targeted Solid Tumors and Hematological Malignancies Presented at AACR-NCI-EORTC International Conference591
  Nov 05, 2015: Syros Pharmaceuticals to Present Preclinical Data on First-in-Class Selective CDK7 Inhibitor Program at American Society of Hematology Annual Meeting601
  Oct 26, 2015: Data to be Presented on CYC065, Cyclacel's CDK2/9 Inhibitor, at AACR-NCI-EORTC International Conference601
  Oct 22, 2015: Cyclacel Doses First Patient in Phase 1 Trial of Its Novel CDK2/9 Inhibitor, CYC065, for the Treatment of Advanced Solid Tumors611
Appendix622
  Methodology621
  Coverage621
  Secondary Research621
  Primary Research621
  Expert Panel Validation621
  Contact Us621
  Disclaimer631

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Cyclin-Dependent Kinase 7 (39 kDa Protein Kinase or CDK-Activating Kinase 1 or TFIIH Basal Transcription Factor Complex Kinase Subunit or EC 2.7.11.22) - Pipeline Review, H1 2016" Jun 30, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Cyclin-Dependent-Kinase-7-39-kDa-Protein-Kinase-or-CDK-Activating-Kinase-1-or-TFIIH-Basal-Transcription-Factor-Complex-Kinase-Subunit-or-EC-2-7-11-22-Pipeline-Review-H1-2016-2088-16138>
  
APA:
Global Markets Direct - Market Research. (2016). Cyclin-Dependent Kinase 7 (39 kDa Protein Kinase or CDK-Activating Kinase 1 or TFIIH Basal Transcription Factor Complex Kinase Subunit or EC 2.7.11.22) - Pipeline Review, H1 2016 Jun 30, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Cyclin-Dependent-Kinase-7-39-kDa-Protein-Kinase-or-CDK-Activating-Kinase-1-or-TFIIH-Basal-Transcription-Factor-Complex-Kinase-Subunit-or-EC-2-7-11-22-Pipeline-Review-H1-2016-2088-16138>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.